MedTrace Logo

Ocular Pharmacokinetics After a Single Drop Instillation of T1225 0.5, 1, 1.5% in 91 Healthy Volunteers

NCT00356850 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2006-07-26

No results posted yet for this study

Summary

To evaluate azithromycin tear concentrations after instillation of one drop of one of the three T1225 concentrations (0.5%, 1% and 1.5%) and to evaluate the ocular safety.

Conditions

  • Eye Infections, Bacterial

Interventions

DRUG

Azithromycin

Sponsors & Collaborators

  • Laboratoires Thea

    lead INDUSTRY

Principal Investigators

  • Claude DUBRAY, Professor · Centre de Pharmacologie Clinique - Clermont-Ferrand (France)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-05-31
Completion
2002-06-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00356850 on ClinicalTrials.gov